FDA Designates Daridorexant as Breakthrough Therapy for Pediatric Insomnia

The U.S. FDA has granted Breakthrough Therapy Designation to Idorsia Ltd's daridorexant for treating insomnia disorder in patients aged 10 to under 18. This designation highlights a significant unmet medical need, as no FDA-approved pharmacological treatments currently exist for pediatric insomnia.